FBRX

Forte Biosciences, Inc. is a biotechnology company operating within the healthcare sector. With a market capitalization of $282.61 million and 16 employees, it represents a relatively small player in its industry. The company's financial health is marked by significant losses, with net income totaling -$51,742,000 and EBITDA of -$53,382,000 over the trailing twelve months. Free cash flow was also negative at -$24,480,124. Notably, the company has a cash balance of $93.41 million, but lacks debt information. Margins were non-existent, with gross margin, operating margin, and profit margin all reported as 0.0%. Returns on equity and assets were also negative, at -110.7% and -58.1%, respectively. Valuation metrics are somewhat unusual, with a forward P/E ratio of -6.49 and an EV/EBITDA of -3.54. The price to book ratio was 4.78. The company's beta is 3.22, indicating potentially high volatility relative to the market.